KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial.

Peter J Goadsby, Jessica Ailani, David W Dodick, Amaal J Starling, Chengcheng Liu, Yingyi Liu, Sung Yun Yu, Jonathan H Smith, Elimor Brand-Schieber, Joel M Trugman

Nat Med 31(7) 2179-2185

PMID40355614
PMCIDPMC12283353
DOI10.1038/s41591-025-03679-7
发表日期2025-05-12
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 flow diagram;Fig. 2:AI 判定为 other。
摘要

摘要

PRODROME was a phase 3, placebo-controlled, double-blind crossover trial evaluating whether ubrogepant 100 mg, a calcitonin gene-related peptide receptor antagonist, dosed during the premonitory (prodromal) phase of migraine, prevented development of headache and resolved prodromal symptoms. Qualifying prodromal events were defined as attacks with symptoms in which the participant was confident headache would follow within 1-6 h. Of 1,087 screened participants, 477 formed the efficacy analysis population. Outcomes were collected across 48 h showing, for example, at 2 h post-dose, absence of photophobia in 19.5% and 12.5% of ubrogepant- and placebo-treated events, respectively (odds ratio (OR) = 1.72 (95% confidence interval (CI) = 1.13-2.61)); at 3 h post-dose, absence of fatigue occurred in 27.3% and 16.8% (OR = 1.85 (95% CI = 1.17-2.92)) and absence of neck pain in 28.9% and 15.9% (OR = 2.04 (95% CI = 1.25-3.32)) of events; at 4 h post-dose, absence of phonophobia in 50.7% and 35.8% (OR = 1.97 (95% CI = 1.38-2.80)) of events; and at 24 h post-dose, absence of dizziness in 88.5% and 82.3% (OR = 1.82 (95% CI = 1.00-3.30)) of events. At 1 h and 6 h post-dose, respectively, absence of difficulty concentrating occurred in 8.7% and 2.1% (OR = 4.26 (95% CI = 1.17-15.54)) and absence of difficulty thinking occurred in 56.9% and 41.8% (OR = 2.05 (95% CI = 1.14-3.71)) of events. Treatment with ubrogepant during the prodromal phase may ameliorate common prodromal symptoms, with improvements possibly as early as 1 h post-dose.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1. Participant flow. Purple boxes and arrows indicate the number and flow of qualifying prodrome events treated with ubrogepant. Gray boxes and arrows indicate the number and flow of qualifying prodrome events treated with placebo. mITT, modified intention-to-treat.
非 KM Figure
Fig. 2Fig. 2. Prodromal symptoms of any intensity for the most common prodromal symptoms at timepoints post-dose. The percentage of participants continuing to have prodromal symptoms at timepoints post-dose are shown. a – g , Participants who reported the prodromal symptoms at pre-dose: sensitivity to light (placebo, n = 273 of 449, ubrogepant 100 mg, n = 273 of 448) ( a ); tired, sleepy or fatigue (placebo, n = 226 of 449, ubrogepant 100 mg, n = 227 of 448) ( b ); neck pain or stiff neck (placebo, n = 180 of 449, ubrogepant 100 mg, n = 180 of 448) ( c ); sensitivity to sound (placebo, n = 162 of 449, ubrogepant 100 mg, n = 161 of 448) ( d ); dizziness, lightheaded, vertigo or imbalance (placebo, n = 139 of 449, ubrogepant 100 mg, n = 130 of 448) ( e ); difficulty concentrating (placebo, n = 101 of 449, ubrogepant 100 mg, n = 103 of 448) ( f ); and difficulty thinking (placebo, n = 74 of 449, ubrogepant 100 mg, n = 69 of 448) ( g ).
非 KM Figure